Highline Wealth Partners LLC Buys Shares of 1,000 CRISPR Therapeutics AG (NASDAQ:CRSP)

Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,000 shares of the company’s stock, valued at approximately $39,000.

Other large investors have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new position in CRISPR Therapeutics in the second quarter worth about $35,000. National Bank of Canada FI increased its holdings in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the third quarter worth $43,000. Finally, Elkhorn Partners Limited Partnership acquired a new position in CRISPR Therapeutics in the second quarter worth $54,000. 69.20% of the stock is currently owned by institutional investors.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CRSP has been the topic of a number of research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Bank of America cut their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Barclays cut their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Stock Down 4.2 %

CRISPR Therapeutics stock traded down $1.73 during midday trading on Friday, hitting $39.56. The company’s stock had a trading volume of 1,618,532 shares, compared to its average volume of 1,599,980. CRISPR Therapeutics AG has a 12 month low of $38.20 and a 12 month high of $91.10. The company has a market capitalization of $3.38 billion, a PE ratio of -13.98 and a beta of 1.68. The stock’s 50-day moving average price is $46.39 and its 200-day moving average price is $48.83.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the business earned ($1.41) earnings per share. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.